Actionable data,
Better connected
ARWEN is the Actionable Real World Evidence Network, created to help you effortlessly participate in vital research and increase the research output of your hospital – while you stay in full control and ownership of your data.
Join Once, Benefit Continuously
ARWEN: a quickly expanding pan-European network for forward-thinking hospitals, healthcare professionals and researchers with a passion for an ever-growing program of Real-World Evidence research.
Latest updates
We have the answer to your questions
Actionable Real World Evidence Network
A standardised,
fit-for-purpose platform
We offer a platform to connect supply and demand of drug-related research questions on our network.
With high-class
extraction support
We support you in extraction, validation and linkage of data to keep additional effort and costs to a minimum.
That unlocks the value in your data
We help you to participate in more research and increase financial rewards and academic returns.
Enabling meaningful
collaboration
We enable you to collaborate with regulatory parties, insurance companies and pharma to do more RWE based research.
ARWEN ensures continuous control of your data
Your data is yours
You are not our product, and neither is your data. We are data analysts, not data brokers.
Your data is safe
The privacy and security of your data always come first. We hold ourselves to the same standards as you do.
Your data is valuable
How you unlock the value in your data, is your choice. We work to turn data into value, in full transparency.
Your data is vital
Your data holds the potential to fast-track crucial research. We are proud to be a highly respected and trusted 3rd party.
Join running studies and enroll in new projects
Drug use &
epidemiology analysis
Main Qs answered
How many and what types of patients are using a drug? How many are eligible?
Examples of typical projects
- Epidemiology study
- Patient group analysis and segmentation
- (Medicine) treatment pattern analysis
Standard of care &
patient pathway analysis
Main Qs answered
How are patients treated in the hospitals?
Examples of typical projects
- Analysis of patient pathways
- Treatment adherence to guidelines
- Segmentation of patient groups by treatment modality
- Identification of improvement areas
Drug impact analysis on outcomes & costs
Main Qs answered
What is / will be the impact of a drug on the hospital (pathway, costs, outcomes, etc.)?
Examples of typical projects
- Impact of drugs on hospital costs, efficiency and patient outcomes
- Horizon scanning (analysis of impact of upcoming drugs)
- Drug effectiveness comparison
Frequently asked questions
ARWEN makes your Real-World Data (RWD) more actionable: increasing the research output of your hospital in a way that is fast, scalable and transparently generates revenues. With ARWEN collecting, standardising and analysing RWD to participate in more academically & financially rewarding research, shouldn’t have to be a struggle.
As a launching partner, you will get the first pick on which studies and programmes to join. This is beneficial given most studies and programmes have limited spots.
We don’t just help hospitals easily apply and join Real-World Evidence (RWE) research opportunities, but we enable the research itself, solving the major pain points that are hampering current studies.
We aim to speed up the generation of insights in the real-world to provide actionable insights to improve healthcare.
There is no investment needed from the hospitals. The hospitals receive financial returns when participating in studies, but no financial investment is asked of the hospitals when participating in ARWEN.
As a member of ARWEN, you have access to research outcomes, benchmarked data and best practices that offer ways to improve the (cost) efficiency and quality of your care – whilst leaving you in full control of your hospital’s data.
And you contribute to scientific research improving medical knowledge turning data into better healthcare.
No. ARWEN was founded by LOGEX after seeing the barriers that hold many of its healthcare clients back when trying to participate in RWE research. LOGEX believes it can help remove these barriers whilst remaining a trusted and impartial third party. That is why it chose to fund the start-up of ARWEN entirely independently.
The hospital is always the data controller, in compliance with GDPR terms. ARWEN ensures continuous control of hospitals on your data:
- Your data is yours – ARWEN is not a data broker
- Your data is safe – The privacy and security of your data always comes first
- Your data is valuable – ARWEN provides clear and transparent financial benefits
- Your data is vital – We are proud to support your ambition to help fast-track crucial research
Patient-level data will not be shared. We are GDRP compliant, so only aggregated anonymised data will be shared with the hospital’s permission. For most studies, this will only be on a population level. Additional permission for sharing aggregated anonymised data at the hospital level is always needed.
ARWEN is powered by LOGEX. An industry-leading healthcare analytics company. LOGEX deploys data security and privacy by design. Our dedicated information security office monitors security procedures in-depth, assuring your data is safe and secure. In addition, we support multiple user authorisation levels to control the privacy and transparency of your data.
We are fully GDPR compliant and ISO27001 certified.
ARWEN does not sell anonymised data. ARWEN ensures continuous control of your data. ARWEN is not a data broker.
The Data Processing Agreement (DPA) specifies the data retention period.
When a hospital is participating in a study with their RWD, the hospital will be entitled to a percentage royalty on the revenues depending on the role of the hospital.
Open running studies and programmes
To obtain a longitudinal view of patients, we require at least three years of routine healthcare data- collected in all hospitals. This includes prescription data, medical procedures, and diagnosis codes (usually expressed as ICD10-codes).
Complex RWE studies
The ambition of ARWEN is to enable complex RWE studies and programmes. Additional data sources such as pathology data, laboratory data, imaging data, and clinical outcomes are collected and linked to understand the patient treatment and outcomes fully.
At LOGEX, we have worked for hospitals since 2008. In the past years, we have supported the extraction and analytics of RWD in local and international initiatives. For example, standards of care, the impact of COVID, patient pathway optimisation. We believe that collecting, standardising and analysing data to participate in more RWE research should not have to be a struggle; that is why we are forming ARWEN.
